<DOC>
	<DOC>NCT00964262</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Healthy male subjects aged 2045 years at screening Body weight over 50 kg, inclusive, and within 20% of ideal body weight Has a present illness or medical history of hepatic, renal, respiratory, cardiovascular disease, blood tumor, mental disorder, and endocrinologic disorder, especially diabetes mellitus Has a sign or symptom or history related to an acute or chronic pancreatitis Has a known allergy or hypersensitivity to exenatide or other drugs such as aspirin, antibiotics, and so on Has ever been exposed to exenatide Shows SBP &gt;= 150 mmHg or &lt;= 90 mmHg or DBP &gt;= 100 mmHg or &lt;= 50 mmHg Has a presence or history of drug abuse Uses any prescription drug, herbal medicine within 2 weeks or OTC drugs or vitamin within 1 week prior to study drug administration Has been participated in other clinical trial within 2 months Has experience of a blood donation during 2 months or a blood transfusion during 1 month prior to study drug administration Heavy smoker more than 10 cigarettes/day within 3 months prior to screening Continuous drinker (over 21 units/week, 1 unit = 10 g of pure alcohol) or subject who can't quit drinking nor smoking during clinical trial period Subjects not eligible at the discretion of investigators</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>SR exenatide</keyword>
	<keyword>Peptron</keyword>
</DOC>